A phase 1/2 trial of VRT106 in glioma & glioblastoma, run by Guangzhou Virotech Pharmaceutical Co., Ltd., now recruiting.
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma is a phase 1/2 interventional study registered as NCT07093814 by Guangzhou Virotech Pharmaceutical Co., Ltd., with 42 participants planned, started 2025-09-02 and due to reach its primary completion in 2028-12-31. Interventions recorded: VRT106.
Shares Guangzhou Virotech Pharmaceutical, Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.